Health Affairs, 23, no. 1 (2004): 9 doi: 10.1377/hlthaff.23.1.9 © 2004 by Project HOPE	New Online   House Health Reform Bill   Paying for Reform   Vetting AHIP's Report   HIV/AIDS Costs   Brief: Insurance Reform   HA Blog Top 10

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

Industry Priorities

Priorities In The Pharmaceutical Industry

PROLOGUE: Among the controversial issues that have arisen in health policy in recent years, none has been more contentious—or engaged public attention more vigorously—than the accelerated growth of pharmaceutical use and spending and related concerns about drug prices. The debate centers on the question of whether high prices for new, on-patent drugs are excessive or reasonable in relation to the costs of research and development (R&D). The complexity and prolonged time span of pharmaceutical R&D make these questions particularly difficult to answer clearly and decisively. Further complicating the picture, the pharmaceutical industry has been undergoing major structural change, as the . . . [Full Text of this Article]

                      What's this?